Symptomatology and level of satisfaction in patients using the double‐J ureteral stent

Abstract

Background: Ureteral stents are used as temporary or permanent drainage measures for intrinsic or extrinsic occlusions of the upper urinary tract. Their use can cause complications such as urinary symptoms, which consequently impact the quality of life. Therefore, the aim of this study was to analyze the symptoms and level of satisfaction of patients who used the double-J ureteral stent.

Methods: This article is a cross-sectional study involving 40 volunteers who had previously undergone a urological procedure that required the insertion of a double-J ureteral stent. Subsequently, they consulted the urology outpatient clinic and answered a questionnaire designed by the authors.

Results: According to the results, the average age of the patients was 43 years old, 75% were female, and 42.5% reported comorbidities, with hypertension being the most prevalent. The wired double-J ureteral stent was used in 72.5% of patients, and the average length of stay was 6 days. 95% of the patients had complaints related to the use of the double-J ureteral stent, with colicky abdominal pain being the most frequent symptom (77.5%) and hematuria being the most common urinary symptom (65%), followed by dysuria (62.5%) and urgency (52.5%). Analysis of the level of satisfaction showed that 55% of patients were satisfied and 22.5% were dissatisfied. No statistical significance was found between the incidence of symptoms related to the double-J ureteral stent and the groups analyzed.

Conclusion: This study was able to highlight important features of the symptomatology of patients using the double-J ureteral stent and the repercussions on satisfaction with its use. Furthermore, it was possible to concluded that the experience of using the double-J ureteral stent was satisfactory for 55% of the patients.

Keywords

double-J ureteral stent / satisfaction / urinary symptoms

References

[1] Rao NP , Preminger GM , Kavanagh JP . Urinary tract stone disease. Springer; 2011.

[2] Cadena IR . Calidad de vida y catéteres ureterales. Su impacto en la población adolescente. Espanha: Universidad Internacional de Andalucía, Curso Máster Universitario en Urología Pediátrica; 2017.

[3] Ulker V , Atalay HA , Cakmak O , Yucel C , Celik O , Kozacioglu Z . Smartphone-based stent tracking application for prevention of forgotten ureteral double-J stents: a prospective study. Int Braz J Urol [Internet]. 2019; 45 (2): 376- 83.

[4] Tolley D . Ureteric stents, far from ideal. Lancet. 2000; 356 (9233): 872- 3.

[5] Joshi HB , Newns N , Stainthorpe A , Macdonagh RP , Keeley FX , Timoney AG . Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003; 169: 1060- 4.

[6] Maldonado AM , Garduño AL , Jungfermann GR , Manzanilla GHA , Rosas NE , Procuna HN , et al. Efficacy of Tamsulosin, Oxybutynin, and their combination in the control of double-j stent-related lower urinary tract symptoms. Int Braz J Urol. 2016; 42 (3): 487- 93.

[7] Zhang L , Li J , Pan M , Han W , Liu S , Xiao Y . Doxazosin oral intake therapy to relieve stent-related urinary symptoms and pain: a prospective, randomized, controlled study. Int Braz J Urol. 2016; 42: 727- 33.

[8] Santos RCM , Moreira RSL , Roza BA . Validação do instrumento Ureteral Stent Symptom Questionnaire para uso no Brasil. Acta Paul Enferm [Internet]. 2016; 29 (2): 198- 204.

[9] Abt D , Dötzer K , Honek P , Müller K , Engeler DS , Burger M , et al. The German linguistic validation of the Ureteral Stent Symptoms Questionnaire (USSQ). World J Urol. 2016; 35 (3): 443- 7.

[10] Tanidir Y , Mangir N , Sahan A , Sulukaya M . Turkish version of the Ureteral Stent Symptoms Questionnaire: linguistic and psychometric validation. World J Urol. 2016; 35 (7): 1149- 54.

[11] Olvera-Posada D , Suárez-Santos M , Castillejos-Molina R , Gabilondo-Navarro F , Méndez-Probst CE . Validation of the Spanish version of ureteral stent symptom questionnaire:prevalence of symptoms in a tertiary care center in Mexico. J Endourol. 2014; 28 (3): 377- 82.

[12] Zhu C , Qu J , Yang L , Feng X . The Chinese linguistic validation of the ureteral stent symptom questionnaire. Urol Int. 2018; 102 (2): 1- 5.

[13] Coyne KS , Sexton CC , Thompson CL , Milsom I , Irwin D , Kopp ZS , et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009; 104 (3): 352- 60.

[14] Amaro JL , Tomé ALF . Proteus:palestras e reuniões organização para preparação ao título de especialista em urologia SBU. São Paulo: Plankmark, 2017. 'SBU-Sociedade Brasileira de Urologia'. p. 21- 41.

[15] Vidigal DJA , Silva AL . Resende, D.F . Doentes atendidos no ambulatório de urologia do sistema único de saúde-Departamento municipal de assintência à saúde pública (SUS -DEMASP) Barbacena-Minas Gerais. Revista Med Minas Gerais. 2006; 16 (2): 74- 8.

[16] Seitz C , Fajkovic H . Epidemiological gender-specific aspects in urolithiasis. World J Urol. 2013; 31 (5): 1087- 92.

[17] Knoll T , Schubert AB , Fahlenkamp D , Leusmann DB , Wendt-Nordahl G , Schubert G . Urolithiasis through the ages: data on more than 200,000 urinary stone analyses. J Urol. 2011; 185 (4): 1304- 11.

[18] Silva GRN , Maciel LC . Epidemiology of urolithiasis consultations in the Paraíba Valley. Rev Col Bras Cir. 2016; 43 (6): 410- 5.

[19] EAU Guidelines. Edn. presented at the EAU Annual Congress London; 2018.

[20] Vega VA , García AD , García AJC . Evaluación de clínica y calidad de vida con catéteres ureterales de tipo doble pig-tail. Actas Urol Esp. 2007; 31 (7): 738- 42.

[21] Joshi HB , Okeke A , Newns N , Keeley FX , Timoney AG . Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002; 59: 511- 6.

[22] Joshi HB , Stainthorpe A , MacDonagh RP , Keeley FX , Timoney AG . Indwelling ureteral stents:evaluation of symptoms, quality of life and utility. J Urol. 2003; 169: 1065- 9.

[23] Leibovici D , Cooper A , Lindner A , Ostrowsky R , Kleinmann J , Velikanov S , et al. Ureteral stents: morbidity and impact on quality of life. Isr Med Assoc J [Internet]. 2005; 7: 491- 4.

[24] Auge BK , Sarvis JA , L'Esperance JO , Preminger GM . Practicepatterns of ureteral stenting after routine ureteroscopic stone surgery: a survey of practicing urologists. J Endourol. 2007; 21: 1287- 92.

[25] Canepa G , Conzi G , Capponi G , Campodonico F , Maffezzini M . Short-time ureteral catheterization after operative ureteroscopic lithotripsy: an alternative to stent versus no stent evaluated in a retrospective study. Arch Ital Urol Androl. 2009; 81 (1): 43- 5.

[26] Shigemura K , Yasufuku T , Yamanaka K , Yamahsita M , Arakawa S , Fujisawa M . How long should double J stent be kept in after ureteroscopic lithotripsy? Urol Res. 2011; 40 (4): 373- 6.

[27] Beysens M , Tailly TO . Ureteral stent in urolithiasis. Asian J Urol. 2018; 5: 274- 86.

[28] Deliveliotis C , Chrisofos M , Gougousis E , Papatsoris A , Dellis A , Varkarakis IM . Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology. 2006; 67: 35- 9.

[29] He F , Man LB , Li GZ , Liu N . Efficacy of α-blocker in improving ureteralstent-related symptoms: a meta-analysis of both direct and indirect comparison. Drug Des Devel Ther. 2016; 10: 1783- 93.

[30] Wang J , Zhang X , Zhang T , Mu J , Bai B , Lei Y . The role of solifenacin, asmonotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis. World J Urol. 2017; 35: 1669- 80.

RIGHTS & PERMISSIONS

2024 The Author(s). UroPrecision published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.